Skip to main content

Table 6 Panel expressions of combining at least two immunostains in endocervical and endometrial adenocarcinomas.

From: Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma*

   ECA EMMA p-value
MUC1* & P16 MUC1+, P16- 0 (0%) 10 (100%) 0.001
  MUC1-, P16+ 8 (100%) 0 (0%)  
MUC1 & VIM MUC1+, VIM+ 1 (7.7%) 9 (69.2%) 0.004
  MUC1-, VIM- 12 (92.3%) 4 (30.8%)  
MUC1 & ER MUC1+, ER+ 0 (0%) 13 (100%) 0.001
  MUC1-, ER- 9 (100%) 0 (0%)  
MUC1 & PR MUC1+, PR+ 0 (0%) 12 (72.2%) 0.001
  MUC1-, PR- 9 (100%) 0 (27.8%)  
P16 & VIM P16-, VIM+ 0 (0%) 7 (77.8%) 0.002
  P16+, VIM- 9 (100%) 2 (22.2%)  
P16 & ER P16-, ER+ 1 (11.1%) 14 (93.3%) 0.001
  P16+, ER- 8 (88.9%) 1 (6.7%)  
P16 & PR P16-, PR+ 2 (18.2%) 13 (92.9%) 0.001
  P16+, PR- 9 (81.8%) 1 (7.1%)  
VIM & ER VIM+, ER+ 0 (0%) 9 (90%) 0.001
  VIM-, ER- 10 (100%) 1 (10%)  
VIM & PR VIM+, PR+ 0 (0%) 8 (88.9%) 0.001
  VIM-, PR- 10 (100%) 1 (11.1%)  
ER & PR ER+, PR+ 2 (16.7%) 15 (100%) 0.001
  ER-, PR- 10 (83.3%) 0 (0%)  
MUC1, ER & PR MUC1+, ER+, PR+ 0 (0%) 11 (100%) 0.001
  MUC1-, ER-, PR- 8 (100%) 0 (0%)  
  1. ECA, endocervical adenocarcinoma; EMMA, endometrial mucinous adenocarcinoma. * Apical and cytoplasmic MUC1 expression.